ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

BEKHealth Introduces Galileo - Research Network Trial Feasibility Solution to Evaluate Protocols With Greater Speed, Precision, and Efficiency

Galileo provides real-time visibility across a clinical research network's entire patient population, reducing the time it takes to accurately evaluate a prospective clinical trial from weeks to an hour

STAMFORD, Conn. - October 7, 2021 - (Newswire.com)

BEKHealth, a Clinical Research Platform company, today announced the introduction of Galileo, the most advanced trial and research network-level feasibility solution. Galileo enables research networks to accurately and efficiently evaluate clinical trial protocols in a standardized way across all locations. Galileo is the latest in BEKHealth's expanding portfolio of solutions designed to automate and streamline clinical research processes and improve business performance.

By providing real-time visibility across a system's entire patient network, users can expand the number of trials they perform and the access in underserved locations. Galileo is the first tool that can be used by any healthcare professional to rapidly, comprehensively and accurately determine if a research network location is suitable for a clinical research trial protocol within a matter of hours. It provides organizations that are seeking to expand research the ability to proactively evaluate untapped disease states and work more collaboratively with sponsors.

"Healthcare organizations are constantly approached with requests to conduct research, and determining which trials are a right fit for the patient network can be incredibly time-consuming," said Jason Baumgartner, founder and CEO of BEKHealth. "Galileo dramatically increases the speed and precision with which feasibility studies for any clinical trial request can be completed, eliminating the inefficiencies of building complex queries and the laborious nature of cross-referencing multiple data sources."

Galileo is prebuilt with a clinical trial library of 24 million medical terms relevant to researchers. The platform ingests unstructured EMR data and translates it into language and clinical terminology used in protocols, resulting in a more accurate capture of a larger pool of eligible patients. The platform also enables researchers to obtain deeper geographic and demographic information about the patient population across all practice groups and satellite locations from a centralized location.

"Like all BEKHealth's solutions, Galileo was built for researchers by researchers and with a deep understanding of the challenges healthcare organizations face in managing and vetting clinical trial requests," Josh Ransom, VP of Customer Experience, noted. "In building an industry-first tool that evaluates the entire protocol, we're helping healthcare organizations focus on the clinical trials that make sense based on their patient populations, increasing the success rates of the trials themselves."

About BEKHealth:
BEKHealth Corp. enables healthcare organizations of all sizes to quickly enter or expand clinical research by combining a proprietary EMR data processing engine with easy-to-use and impactful user tools to accelerate business performance. For more information, visit http://www.bekhealth.com.




Press Release Service by Newswire.com

Original Source: BEKHealth Introduces Galileo - Research Network Trial Feasibility Solution to Evaluate Protocols With Greater Speed, Precision, and Efficiency
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.